Closely-held Breath Therapeutics appointed Peter Shadday as chief commercial officer to lead the company’s market access activities and product commercialization.
Mr. Shadday has more than 20 years of global, senior commercial experience in strategic and operational marketing, plus sales functions with leadership roles in the U.S., EU, Latin America and Asia Pacific.
Prior to joining Breath, Mr. Shadday was global marketing lead at Vertex for the next generation corrector programs for the treatment of cystic fibrosis.
He was previously VP and global business leader at Lundbeck, successfully leading the global product launch of Brintellix/Trintellix, a novel antidepressant and key brand. And at Gilead Sciences, he held the positions of director of international and global commercial strategy, and was in charge of the global launch of Viread.
Breath expects its lead program, with inhaled liposomal cyclosporine A (L-CsA) for the treatment of bronchiolitis obliterans, will start Phase 3 clinical trials in the U.S. and Europe in early 2019.
“At this stage, we will begin to prepare and implement a thoroughly studied market access strategy in order to assure the future commercial success of L-CsA in all key markets,” Dr. Jens Stegemann, CEO, said in a statement.
Mr. Shadday said Breath Therapeutics is uniquely suited to develop drug-aerosol therapeutics in pulmonary orphan indications. “The company’s lead drug, L-CsA, is a first-in-class therapy for a true unmet medical need in respiratory medicine,” he added. “This is an outstanding opportunity to bring this drug to market and significantly improve treatment options for patients.”
